icon-folder.gif   Conference Reports for NATAP  
 
  HEPDART 2015: Frontiers in
Drug Development for Viral Hepatitis
December 6-10 2015
Wailea, HI
Back grey_arrow_rt.gif
 
 
 
High Efficacy of Ledipasvir/Sofosbuvir With Ribavirin In HCV Genotype-1 Infected Patients with Decompensated Liver Disease: Analysis by MELD Score from the SOLAR-1 and SOLAR-2 Trials
 
 
  Reported by Jules Levin
HEP DART 2015, December 6-10, 2015, Wailea, HI
 
M Bourliere1, M Charlton2, SL Flamm3, EM Yoshida4, AJ Muir5, MW Fried6, N Terrault7, S Arterburn 8, C Yun 8, PS Pang8, A Osinusi8, DM Brainard8, JG McHutchison8, M Manns9, N Afdhal10
1H˘pital Saint Joseph, Marseilles, France; 2Intermountain Medical Center, Salt Lake City, 3Northwestern University Feinberg School of Medicine, Chicago, US; 4Vancouver General Hospital and University of British Columbia, Vancouver, Canada; 5Duke University, Durham, NC, US; 6University of North Carolina at Chapel Hill / UNC School of Medicine, Chapel Hill, US; 7University of California, San Francisco, US; 8Gilead Sciences Inc., Foster City, US; 9Hannover Medical School, Hannover, Germany; 10Beth Israel Deaconess Medical Center, Boston, US
 
AASLD: Detecting Drug-Induced Liver Injury in Patients With Decompensated Chronic Hepatitis C: A Review of the SOLAR-1 and SOLAR-2 Studies - (11/23/15)

HepDart1.gif

HepDart2.gif

HepDart3.gif

HepDart4.gif

HepDart5.gif

HepDart6.gif

HepDart7.gif

HepDart8.gif

HepDart9.gif

HepDart10.gif

HepDart11.gif

HepDart12.gif